Who wants to let Dr. Jay know about the bold part
Post# of 148097
(Total Views: 671)
Posted On: 06/28/2024 8:45:31 AM
Who wants to let Dr. Jay know about the bold part below from SMC's explanation of their STAM mice model? Seems like it might be a good idea to track these mice for another few weeks to see what's happening with their otherwise inevitable liver cancer.
Maybe Ohm or someone else can speak to whether there's a chance Leron has a chance to show any effect in this way. I'm reminded of the patients apparently lost to follow up in the mtnbc trial that might have been able to show a longer overall survival rate had anyone thought to track them past 12+ months.
(forgive me if I botched any of the follow up/study details as I've been up way too long thanks to my son deciding he should get up at the ass-crack of dawn to sneak some chocolate. Thankfully he sneaks about the house like our resident Lionel Hutz posts. Poorly, and without any idea he's not nearly as clever as he thinks he is)
"Our STAM™ model is a model that recapitulates the same disease progression as human MASH/NASH-HCC. In this model, male C57BL/6 mice aged two days are given a single dose of streptozotocin to reduce insulin secretory capacity. When the mice turn four weeks of age they start a high-fat diet feeding. This model has a background of late type 2 diabetes which progresses into fatty liver, NASH, fibrosis and consequently liver cancer (HCC). Compared to other MASH/NASH-HCC model mice, the disease progresses in a relatively short period of time, and liver cancer is developed in 100% of animals at 20 weeks of age.Thus, our model is widely used in MASH/NASH research, with more than 70 papers (seen left of the figure shown below) and 80 international conferences (listed right of the figure shown below) published using data from our STAM™ model so far."
Maybe Ohm or someone else can speak to whether there's a chance Leron has a chance to show any effect in this way. I'm reminded of the patients apparently lost to follow up in the mtnbc trial that might have been able to show a longer overall survival rate had anyone thought to track them past 12+ months.
(forgive me if I botched any of the follow up/study details as I've been up way too long thanks to my son deciding he should get up at the ass-crack of dawn to sneak some chocolate. Thankfully he sneaks about the house like our resident Lionel Hutz posts. Poorly, and without any idea he's not nearly as clever as he thinks he is)
"Our STAM™ model is a model that recapitulates the same disease progression as human MASH/NASH-HCC. In this model, male C57BL/6 mice aged two days are given a single dose of streptozotocin to reduce insulin secretory capacity. When the mice turn four weeks of age they start a high-fat diet feeding. This model has a background of late type 2 diabetes which progresses into fatty liver, NASH, fibrosis and consequently liver cancer (HCC). Compared to other MASH/NASH-HCC model mice, the disease progresses in a relatively short period of time, and liver cancer is developed in 100% of animals at 20 weeks of age.Thus, our model is widely used in MASH/NASH research, with more than 70 papers (seen left of the figure shown below) and 80 international conferences (listed right of the figure shown below) published using data from our STAM™ model so far."
(15)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼